Brief: Compugen To Present Clinical Data From Anti-TIGIT COM902 Monotherapy And Triple Combination Dose Escalation Studies At SITC 2021
01/10/2021 13:21
Oct 1 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN TO PRESENT CLINICAL DATA FROM ANTI-TIGIT COM902
MONOTHERAPY AND TRIPLE COMBINATION DOSE ESCALATION STUDIES AT
SITC 2021
Source text for Eikon: ID:nPn2x0Snda
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025